Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 478 participants.

Also called NCT06339086

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 478 participants (planned count) (from the registry)
Sponsor
Chengdu Brilliant Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT06339086
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06339086. Randomized; no masking; primary purpose treatment. Start 2024-04 (anticipated); primary completion 2025-08-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Semaglutide Injection
Intervention (Drug)
Semaglutide Injection(Ozempic®)
Intervention (Drug)
Metformin
Lead sponsor
Chengdu Brilliant Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06339086
Content hash
737e7e3d2c5ea8b396087c7e81172659cdf6405541c44c1a3502fbeae28a28b6